Form 4: Rhythm Pharmaceuticals CEO David Meeker Sells Shares to Cover Tax Obligations

Rhythm Pharmaceuticals CEO David Meeker sold 45,494 shares of common stock on March 19, 2024, to cover withholding taxes related to vesting restricted stock units.

Summary

• On March 19, 2024, David P. Meeker, the President and CEO of Rhythm Pharmaceuticals, sold 45,494 shares of common stock.
• The sale was executed at a weighted average price of $39.22 per share, with individual transactions ranging from $39.04 to $39.22.
• The transaction was conducted under a pre-existing Rule 10b5-1 trading plan adopted before February 27, 2023.
• The purpose of the sale was solely to cover withholding taxes associated with the vesting of previously reported restricted stock units.
• Following the transaction, Meeker directly owns 174,605 shares of Rhythm Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment as the sale is related to tax obligations and executed under a pre-existing trading plan, not necessarily indicative of the executive's view on the company's performance.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax obligations. Sales executed under 10b5-1 plans are generally viewed as less indicative of an executive's sentiment on the company's future prospects, as these plans are pre-arranged.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the context of the sale.

Key Dates